Tivoxavir marboxil (TXM) — NDA/BLA submission
Q3 2026
Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studySource filing
TRAW biotech catalysts & pipeline
TRAWS PHARMA INC · Data as of 2026-09-08
Upcoming catalysts
Tivoxavir marboxil (TXM) — Regulatory decision
Late 2026
The Company is preparing a comprehensive response to address the FDA's concerns, with the goal of resolving the hold and advancing the program in the US by the end of 2026.Source filing